Serum Institute Of India Begins Manufacturing Of US Based Codagenix's Potential Covid-19 Vaccine

Serun Institute of India (SII) has begun manufacturing the United States (US) biotech firm Codagenix Inc's potential COVID-19 vaccine, the American company said.

Codagenix also said that it expected to start early-stage human trials of the vaccine candidate by the end of this year in the United Kingdom (UK).

The vaccine candidate CDX-005 by Codagenix is delivered intranasally rather than via an injection.

The SII is the world's largest vaccine manufacturer by quantity of doses produced. It is already working on a number of vaccine candidates against the novel coronavirus -- SarsCoV-2.

One of the most prominent and talked about vaccine candidate the SII is involved with is UK's Covishield, developed by AstraZeneca and Oxford University. The SII may also be its mass-production partner as it is in the last stages of trials.

Apart from conducting trials and potentially mass-producing, the institute is also working to develop its own vaccine candidate.